Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Advanced Solid Tumor 7Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 5Colorectal Neoplasms 5Stomach Neoplasms 4Melanoma 4Carcinoma, Hepatocellular 4Solid Tumor 3Solid Tumors 2Lymphoma 2Head and Neck Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Renal Cell 2Advanced Solid Tumors 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Testicular Germ Cell Tumor 1Skin Neoplasms 1Simpson-Golabi-Behmel syndrome 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Neuroendocrine Tumors 1Neoplasms 1Nasopharyngeal Carcinoma 1Muscle Invasive Bladder Cancer 1

Interventions

Everolimus 10lutetium Lu 177 dotatate 5Magnetic Resonance Spectroscopy 5pasireotide 4Specimen Handling 3Positron Emission Tomography Computed Tomography 3Fluorodeoxyglucose F18 3(177)Lu-DOTA-EB-TATE 3olaparib 2amino-acid, glucose, and electrolyte solution 2Temozolomide 2Nivolumab 2FAPI-46 2veliparib 1vandetanib 1trifluridine tipiracil drug combination 1toripalimab 1tislelizumab 1talazoparib 1surufatinib 1romidepsin 1peposertib 1pembrolizumab 1pelcitoclax 1pegfilgrastim 1fosbretabulin 1fludarabine phosphate 1exemestane 1decitabine and cedazuridine drug combination 1dactolisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neuroendocrine Tumors × tislelizumab × Clear all
NCT05167071 2025-04-27

HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study

Harbour BioMed (Guangzhou) Co. Ltd.

Phase 1 Active not recruiting
53 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡